Disclosed is the use of PKC isoform activators and inhibitors for attenuating inflammation which results from a skin wound. The PKC isoform can be PKC-alpha and the inhibitor can be the n-myristoylated PKC-alpha pseudosubstrate peptide. A growth factor or insulin can be used in conjunction with the PKC inhibitor or activator.